trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'pearl', 'breast']
some impressive oncology pearls 12-months after hem/onc fellowship grad, i found out that breast ca understanding has changed: her2 1+ or 2+ ish-neg are not necessarily her2-neg but her2-low longer pfs &amp; os with trastuzumab deruxtecan. what a practice changing trial!#asco22 
BMT fellow #Tx & #CARTcells @MayoClinic | Previous Hematology-Oncology Fellow @AUB_Lebanon | EBMT Young Ambassador 2018 | My tweets are my own